Lancement au Canada d’un nouveau traitement à dose unique de l’otite externe canine

  • Claro® offre aux vétérinaires un traitement de première ligne efficace qui évite aux propriétaires d’animaux de compagnie de devoir administrer eux-mêmes le médicament

Mississauga, March 11, 2019 – Bayer in Canada announced the launch of Claro®, the only single-dose, veterinarian-administered first-line treatment for canine otitis externa. Claro® is used specifically for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).


Otitis externa is one of the most common reasons dog owners take their dog to a veterinarian. The condition is frustrating for both canine patients and their owners. It is caused by inflammation of the external ear canal and is often accompanied by secondary infections. Otitis externa can cause pain, itching and a strong odour in affected dogs. Most existing treatments require dog owners to apply ear medications at home, which can be challenging.


Claro® is intended to be a first-line treatment for otitis externa that addresses the needs of veterinarians and dog owners. It is a clear liquid solution featuring a fixed combination of antibacterial, antifungal, and anti-inflammatory ingredients that penetrates deep into swollen ear canals. A single dose lasts for 30 days. The unique single-dose veterinarian-administered treatment spares pet owners the frustration of in-home application and eliminates veterinarian uncertainty about pet owner compliance.


For more information on Claro®, please visit


About Claro®

Claro® is indicated for the treatment of canine otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).  A single, 1 ml dose in each affected ear treats dogs of all sizes.


About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to



Corporate Communications



Forward-Looking Statements

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.